You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 451 Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
451 Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy
Free

Authors

Citation

Lamberti G, Ricciuti B, Vaz V, et al
451 Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0451

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.